Corindus Vascular Robotics has been named the recipient of the 2014 North American New Product Innovation Award in Interventional Cardiology. The award was established by growth partnership company Frost & Sullivan to recognise visionary innovation and product excellence. Corindus’s CorPath vascular robotic system is the first medical device to bring robotic precision and accuracy to coronary angioplasty procedures, which may improve clinical outcomes while increasing radiation protection for interventional cardiologists.
“To achieve excellence in new product innovation leadership is not an easy task, but the CorPath system addresses a critical concern of interventional cardiologists, and has the potential to improve outcomes and economics in coronary angioplasty,” notes Greg Caressi, senior vice president, Healthcare & Life Sciences, Frost & Sullivan. “Corindus’s receipt of this award signifies a great accomplishment.”
The CorPath System stood out from other products in the market with the following key differentiators:
• Fulfilling Unmet Needs in Interventional Cardiology. The CorPath System provides tremendous benefits that decrease key career-limiting issues that physicians tend to face as a result of radiation exposure.
• Optimised Design Considerations for Cath Lab Use. The CorPath System was designed to have the physician sitting in the Interventional Cockpit, removed from radiation, in a robotic control unit that sits beside the patient on the patient table bedrail.
• Advancing Care and Safety. The CorPath System can safely navigate through the vascular anatomy to perform balloon stenting techniques.
• Innovative CorPath One Stent Programme. Corindus Vascular Robotics launched the “CorPath One Stent Programme” to highlight the precision and accuracy of the CorPath System by offering a US$1,000 credit to hospitals that use two or more stents per lesion in coronary angioplasties performed with CorPath.
• Future Promise. The CorPath System is believed to have a future in emerging interventional techniques and could be leveraged for procedures in other related fields.
Corindus chief executive officer David Handler says, “We are committed to pioneering a positive change in the delivery of healthcare and making a significant difference for patients, physicians and hospitals. Frost & Sullivan has validated that the direction we are moving in is the right one. On behalf of Corindus, we would like to express our thanks for this esteemed honour.”
